215 related articles for article (PubMed ID: 33477404)
1. A Phase IIb Randomized Controlled Trial Investigating the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease.
Koay YY; Tan GCJ; Phang SCW; Ho JI; Chuar PF; Ho LS; Ahmad B; Abdul Kadir K
Nutrients; 2021 Jan; 13(1):. PubMed ID: 33477404
[TBL] [Abstract][Full Text] [Related]
2. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
3. Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial.
Chuar PF; Ng YT; Phang SCW; Koay YY; Ho JI; Ho LS; Botross Henien NP; Ahmad B; Abdul Kadir K
Nutrients; 2021 Oct; 13(11):. PubMed ID: 34836025
[TBL] [Abstract][Full Text] [Related]
4. Tocotrienol-rich vitamin E improves diabetic nephropathy and persists 6-9 months after washout: a phase IIa randomized controlled trial.
Tan GCJ; Tan SMQ; Phang SCW; Ng YT; Ng EY; Ahmad B; Palamisamy UDM; Kadir KA
Ther Adv Endocrinol Metab; 2019; 10():2042018819895462. PubMed ID: 31903178
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial.
Ng YT; Phang SCW; Tan GCJ; Ng EY; Botross Henien NP; M Palanisamy UD; Ahmad B; Abdul Kadir K
Nutrients; 2020 May; 12(5):. PubMed ID: 32456230
[TBL] [Abstract][Full Text] [Related]
6. Sodium Bicarbonate Supplementation and Urinary TGF-
Raphael KL; Greene T; Wei G; Bullshoe T; Tuttle K; Cheung AK; Beddhu S
Clin J Am Soc Nephrol; 2020 Feb; 15(2):200-208. PubMed ID: 31974286
[TBL] [Abstract][Full Text] [Related]
7. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
Nangaku M; Takama H; Ichikawa T; Mukai K; Kojima M; Suzuki Y; Watada H; Wada T; Ueki K; Narita I; Kashihara N; Kadowaki T; Hase H; Akizawa T
Nephrol Dial Transplant; 2023 May; 38(5):1204-1216. PubMed ID: 36002026
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients.
Daud ZA; Tubie B; Sheyman M; Osia R; Adams J; Tubie S; Khosla P
Vasc Health Risk Manag; 2013; 9():747-61. PubMed ID: 24348043
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.
Huang B; Wen W; Ye S
Front Endocrinol (Lausanne); 2022; 13():880930. PubMed ID: 35634488
[TBL] [Abstract][Full Text] [Related]
12. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
13. A Prospective, Multicentered, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Keluoxin Capsules in the Treatment of Microalbuminuria in Patients with Type 2 Early Diabetic Kidney Disease.
Zhao J; Wang S; Li X; Zhang G; Xu Y; Zheng X; Guo J; Zhang Z
J Integr Complement Med; 2024 Feb; 30(2):185-195. PubMed ID: 37733303
[No Abstract] [Full Text] [Related]
14. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios.
Ren H; Shao Y; Ma X; Yang M; Liu Y; Wang Q
J Diabetes Complications; 2019 Jul; 33(7):477-484. PubMed ID: 31097304
[TBL] [Abstract][Full Text] [Related]
15. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
[TBL] [Abstract][Full Text] [Related]
16. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.
Wada T; Inagaki M; Yoshinari T; Terata R; Totsuka N; Gotou M; Hashimoto G
Clin Exp Nephrol; 2021 Feb; 25(2):120-130. PubMed ID: 32974732
[TBL] [Abstract][Full Text] [Related]
17. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
Jin D; Huang WJ; Meng X; Yang F; Bao Q; Zhang MZ; Yang YN; Ni Q; Lian FM; Tong XL
Trials; 2019 Dec; 20(1):756. PubMed ID: 31864393
[TBL] [Abstract][Full Text] [Related]
18. Increased urinary excretion of hedgehog interacting protein (uHhip) in early diabetic kidney disease.
Miyata KN; Zhao XP; Chang SY; Liao MC; Lo CS; Chenier I; Ethier J; Cailhier JF; Lattouf JB; Troyanov S; Chiasson JL; Ingelfinger JR; Chan JSD; Zhang SL
Transl Res; 2020 Mar; 217():1-10. PubMed ID: 31794697
[TBL] [Abstract][Full Text] [Related]
19. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study.
Koeda Y; Tanaka F; Segawa T; Ohta M; Ohsawa M; Tanno K; Makita S; Ishibashi Y; Itai K; Omama SI; Onoda T; Sakata K; Ogasawara K; Okayama A; Nakamura M
BMC Nephrol; 2016 May; 17(1):46. PubMed ID: 27169575
[TBL] [Abstract][Full Text] [Related]
20. The effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
Khatami PG; Soleimani A; Sharifi N; Aghadavod E; Asemi Z
J Clin Lipidol; 2016; 10(4):922-929. PubMed ID: 27578124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
